Detail akcie Biomarin Pharma online

Business Summary: BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Biomarin Pharmaceutical Inc revenues increased 15% to $1.57B. Net income increased from $195.8M to $426.2M. Revenues reflect Voxzogo segment increase of 29% to $435.1M, Palynziq1 segment increase of 21% to $199.2M, Rest of the world segment increase of 69% to $268.8M, United States segment increase of 22% to $514.2M.